At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 219 enrolled
Drug / intervention
LEO 90100 Aerosol Foam +1 moredrug
Likely dose
LEO 90100 Aerosol Foam 50 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial Gathering Insight of Patient Reported Factors That Influence Preference Following Once Daily Topical Treatment With LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
In Brief
A Phase 3 clinical trial evaluating LEO 90100 Aerosol Foam and Daivobet® gel for Psoriasis Vulgaris. Completed, enrolled 219 participants across 1 site.
Detailed Summary
To gather insight on how product attributes affect usability by investigating the factors that are thought to influence patient preference to topical anti-psoriatic treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionJul 2015
TodayJul 2026
First PostedDec 8, 2014
Enrollment StartJan 1, 2015
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.6 years ago
Interventions
LEO 90100 Aerosol Foamdrug
Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
Daivobet® geldrug
Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.